About concomitant KRAS and other molecular alterations in non–small cell lung cancers

About concomitant KRAS and other molecular alterations in non–small cell lung cancers

In this letter, we aim to report the frequency of double mutants (ie, KRAS and another oncogenic alteration) in a case series of patients with advanced NSCLC tested for EGFR, ALK, ROS1, BRAF and KRAS alterations for therapeutic purposes. [...]beyond the classical mutual exclusivity of driver molecul...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Human pathology 2019-05, Vol.87, p.115-116
Hauptverfasser: Bourhis, Amélie, Quintin-Roué, Isabelle, Uguen, Arnaud
Format: Artikel
Sprache:eng
Schlagworte:
Immunology
Life Sciences
Lung cancer
Mutation
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 116
container_issue
container_start_page 115
container_title Human pathology
container_volume 87
creator Bourhis, Amélie
Quintin-Roué, Isabelle
Uguen, Arnaud
description In this letter, we aim to report the frequency of double mutants (ie, KRAS and another oncogenic alteration) in a case series of patients with advanced NSCLC tested for EGFR, ALK, ROS1, BRAF and KRAS alterations for therapeutic purposes. [...]beyond the classical mutual exclusivity of driver molecular alterations in NSCLC, some samples can nevertheless contain double mutations. The necessity of diagnosing double mutations emphasizes the need to analyze concurrently the panel of EGFR, BRAF, ALK, ROS1 and KRAS genes [5].Acknowledgements The authors would like to acknowledge the technical staff of the Department of Pathology (CHRU Brest) for their contributions in molecular analyses as well as the thoracic oncologists and molecular geneticists of the Brest University Hospital for their daily collaboration.
doi_str_mv 10.1016/j.humpath.2019.01.003
format Article
fullrecord <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_02262441v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0046817719300164</els_id><sourcerecordid>2185567268</sourcerecordid><originalsourceid>FETCH-LOGICAL-c422t-676ba9273c003e5a034921b823ba760624be03ec8cf961059748362f8e4493843</originalsourceid><addsrcrecordid>eNqFkc2KFDEUhYMoTjv6CErAzbio8ua_aiXNoI7YIPiDy5BKp-00VUmbpAbc-Q6-oU9iim5n4cZNAsl3zz33HoSeEmgJEPny0O7n6WjKvqVA-hZIC8DuoRURjDYd6-l9tALgsumIUhfoUc4HAEIEFw_RBQPVy56pFfq6HuJcsI3BxskXEwp-_3H9CZuwxbHsXcJTHJ2dR5OwGYtLpvgYMvYBhxh-__yVJzOO2Lp6jHP4hq0J1qX8GD3YmTG7J-f7En158_rz9U2z-fD23fV601hOaWmkkoPpqWK2unfCAOM9JUNH2WCUBEn54OqH7eyulwREr3jHJN11jvOedZxdohcn3b0Z9TH5yaQfOhqvb9YbvbwBpVWFk1tS2asTe0zx--xy0ZPPi3MTXJyzpqQTQioqu4o-_wc9xDmFOommlAoQisMiKE6UTTHn5HZ3DgjoJSV90OeU9JKSBqLrnLXu2Vl9Hia3vav6G0sFXp0AV1d3613S2XpXF7v1ydmit9H_p8UfJnijwg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2225057401</pqid></control><display><type>article</type><title>About concomitant KRAS and other molecular alterations in non–small cell lung cancers</title><source>Elsevier ScienceDirect Journals Complete</source><creator>Bourhis, Amélie ; Quintin-Roué, Isabelle ; Uguen, Arnaud</creator><creatorcontrib>Bourhis, Amélie ; Quintin-Roué, Isabelle ; Uguen, Arnaud</creatorcontrib><description>In this letter, we aim to report the frequency of double mutants (ie, KRAS and another oncogenic alteration) in a case series of patients with advanced NSCLC tested for EGFR, ALK, ROS1, BRAF and KRAS alterations for therapeutic purposes. [...]beyond the classical mutual exclusivity of driver molecular alterations in NSCLC, some samples can nevertheless contain double mutations. The necessity of diagnosing double mutations emphasizes the need to analyze concurrently the panel of EGFR, BRAF, ALK, ROS1 and KRAS genes [5].Acknowledgements The authors would like to acknowledge the technical staff of the Department of Pathology (CHRU Brest) for their contributions in molecular analyses as well as the thoracic oncologists and molecular geneticists of the Brest University Hospital for their daily collaboration.</description><identifier>ISSN: 0046-8177</identifier><identifier>EISSN: 1532-8392</identifier><identifier>DOI: 10.1016/j.humpath.2019.01.003</identifier><identifier>PMID: 30796937</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Immunology ; Life Sciences ; Lung cancer ; Mutation</subject><ispartof>Human pathology, 2019-05, Vol.87, p.115-116</ispartof><rights>2019 Elsevier Inc.</rights><rights>2019. Elsevier Inc.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c422t-676ba9273c003e5a034921b823ba760624be03ec8cf961059748362f8e4493843</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.humpath.2019.01.003$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,315,781,785,886,3551,27929,27930,46000</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30796937$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.univ-brest.fr/hal-02262441$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Bourhis, Amélie</creatorcontrib><creatorcontrib>Quintin-Roué, Isabelle</creatorcontrib><creatorcontrib>Uguen, Arnaud</creatorcontrib><title>About concomitant KRAS and other molecular alterations in non–small cell lung cancers</title><title>Human pathology</title><addtitle>Hum Pathol</addtitle><description>In this letter, we aim to report the frequency of double mutants (ie, KRAS and another oncogenic alteration) in a case series of patients with advanced NSCLC tested for EGFR, ALK, ROS1, BRAF and KRAS alterations for therapeutic purposes. [...]beyond the classical mutual exclusivity of driver molecular alterations in NSCLC, some samples can nevertheless contain double mutations. The necessity of diagnosing double mutations emphasizes the need to analyze concurrently the panel of EGFR, BRAF, ALK, ROS1 and KRAS genes [5].Acknowledgements The authors would like to acknowledge the technical staff of the Department of Pathology (CHRU Brest) for their contributions in molecular analyses as well as the thoracic oncologists and molecular geneticists of the Brest University Hospital for their daily collaboration.</description><subject>Immunology</subject><subject>Life Sciences</subject><subject>Lung cancer</subject><subject>Mutation</subject><issn>0046-8177</issn><issn>1532-8392</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNqFkc2KFDEUhYMoTjv6CErAzbio8ua_aiXNoI7YIPiDy5BKp-00VUmbpAbc-Q6-oU9iim5n4cZNAsl3zz33HoSeEmgJEPny0O7n6WjKvqVA-hZIC8DuoRURjDYd6-l9tALgsumIUhfoUc4HAEIEFw_RBQPVy56pFfq6HuJcsI3BxskXEwp-_3H9CZuwxbHsXcJTHJ2dR5OwGYtLpvgYMvYBhxh-__yVJzOO2Lp6jHP4hq0J1qX8GD3YmTG7J-f7En158_rz9U2z-fD23fV601hOaWmkkoPpqWK2unfCAOM9JUNH2WCUBEn54OqH7eyulwREr3jHJN11jvOedZxdohcn3b0Z9TH5yaQfOhqvb9YbvbwBpVWFk1tS2asTe0zx--xy0ZPPi3MTXJyzpqQTQioqu4o-_wc9xDmFOommlAoQisMiKE6UTTHn5HZ3DgjoJSV90OeU9JKSBqLrnLXu2Vl9Hia3vav6G0sFXp0AV1d3613S2XpXF7v1ydmit9H_p8UfJnijwg</recordid><startdate>201905</startdate><enddate>201905</enddate><creator>Bourhis, Amélie</creator><creator>Quintin-Roué, Isabelle</creator><creator>Uguen, Arnaud</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><general>WB Saunders</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><scope>1XC</scope></search><sort><creationdate>201905</creationdate><title>About concomitant KRAS and other molecular alterations in non–small cell lung cancers</title><author>Bourhis, Amélie ; Quintin-Roué, Isabelle ; Uguen, Arnaud</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c422t-676ba9273c003e5a034921b823ba760624be03ec8cf961059748362f8e4493843</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Immunology</topic><topic>Life Sciences</topic><topic>Lung cancer</topic><topic>Mutation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bourhis, Amélie</creatorcontrib><creatorcontrib>Quintin-Roué, Isabelle</creatorcontrib><creatorcontrib>Uguen, Arnaud</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Human pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bourhis, Amélie</au><au>Quintin-Roué, Isabelle</au><au>Uguen, Arnaud</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>About concomitant KRAS and other molecular alterations in non–small cell lung cancers</atitle><jtitle>Human pathology</jtitle><addtitle>Hum Pathol</addtitle><date>2019-05</date><risdate>2019</risdate><volume>87</volume><spage>115</spage><epage>116</epage><pages>115-116</pages><issn>0046-8177</issn><eissn>1532-8392</eissn><abstract>In this letter, we aim to report the frequency of double mutants (ie, KRAS and another oncogenic alteration) in a case series of patients with advanced NSCLC tested for EGFR, ALK, ROS1, BRAF and KRAS alterations for therapeutic purposes. [...]beyond the classical mutual exclusivity of driver molecular alterations in NSCLC, some samples can nevertheless contain double mutations. The necessity of diagnosing double mutations emphasizes the need to analyze concurrently the panel of EGFR, BRAF, ALK, ROS1 and KRAS genes [5].Acknowledgements The authors would like to acknowledge the technical staff of the Department of Pathology (CHRU Brest) for their contributions in molecular analyses as well as the thoracic oncologists and molecular geneticists of the Brest University Hospital for their daily collaboration.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>30796937</pmid><doi>10.1016/j.humpath.2019.01.003</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0046-8177
ispartof Human pathology, 2019-05, Vol.87, p.115-116
issn 0046-8177
1532-8392
language eng
recordid cdi_hal_primary_oai_HAL_hal_02262441v1
source Elsevier ScienceDirect Journals Complete
subjects Immunology
Life Sciences
Lung cancer
Mutation
title About concomitant KRAS and other molecular alterations in non–small cell lung cancers
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-11T10%3A03%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=About%20concomitant%20KRAS%20and%20other%20molecular%20alterations%20in%20non%E2%80%93small%20cell%20lung%20cancers&rft.jtitle=Human%20pathology&rft.au=Bourhis,%20Am%C3%A9lie&rft.date=2019-05&rft.volume=87&rft.spage=115&rft.epage=116&rft.pages=115-116&rft.issn=0046-8177&rft.eissn=1532-8392&rft_id=info:doi/10.1016/j.humpath.2019.01.003&rft_dat=%3Cproquest_hal_p%3E2185567268%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2225057401&rft_id=info:pmid/30796937&rft_els_id=S0046817719300164&rfr_iscdi=true